COPENHAGEN, August 4, 2026, 20:21 CEST — With Nasdaq Copenhagen closed and trading ongoing in New York, Novo Nordisk’s ADR is falling despite topping Q2 expectations.
- Novo’s ADR dropped 6.8% during intraday trade. The company’s Copenhagen-listed shares finished up 1.75% before the earnings release.
- Adjusted operating earnings surpassed the consensus estimate by 16.2%. The midpoints for guidance increased by five percentage points.
- Weekly prescriptions for Wegovy pills surpassed 265,000. Pipeline impairments totaled DKK 6.3 billion.
Novo Nordisk’s U.S. ADR dropped 6.8% on Tuesday even after the company reported earnings that surpassed expectations. The decline indicates lingering investor doubts about the strength of its recovery.
Danish B shares finished up 1.75% at DKK 307.60. Novo released its results following the 17:00 market close in Copenhagen. New York was the initial venue for full price discovery.
This resulted in an initial reaction gap of 8.6 percentage points. The Danish open on Wednesday now faces the risk of needing to catch up.
| Instrument | Latest price | Day move | Market status |
|---|---|---|---|
| Novo Nordisk ADR | $43.87 | -6.8% | NYSE trading |
| Novo Nordisk B shares | DKK 307.60 | +1.75% | Copenhagen closed ahead of results |
| Eli Lilly NYSE:LLY | $1,118.55 | -0.3% | NYSE trading |
| Health Care Select Sector SPDR (NYSEARCA:XLV) | $162.16 | -0.05% | U.S. trading |
| SPDR S&P 500 ETF Trust NYSEARCA:SPY | $771.59 | +1.8% | U.S. trading |
Novo fell even as the broader market gained. Lilly eased 0.3%, with health care unchanged. Preliminary U.S. prices were posted around 20:06 CEST.
The quarter surpassed immediate earnings expectations. Adjusted operating profit came in at DKK 33.389 billion, exceeding consensus by 16.2%.
| Q2 metric | Result | CER change | Investor comparison |
|---|---|---|---|
| Adjusted sales | DKK 78.488 billion | +7% | H1 adjusted increase came in at +2% |
| Adjusted operating profit | DKK 33.389 billion | +11% | 16.2% ahead of market expectations |
| Reported operating profit | DKK 27.061 billion | -16% | Reflected impairment burden |
Adjusted earnings increased at a quicker pace than revenue. However, reported operating profit declined by 16% on a constant currency basis.
The gap in the reported earnings bridge was significant.
| Profit bridge | Adjusted | Reported | Difference |
|---|---|---|---|
| Operating profit | DKK 33.389 billion | DKK 27.061 billion | DKK 6.328 billion |
| Operating margin | 42.5% | 34.5% | 8.1 points |
| CER profit growth | +11% | -16% | 27 points |
Novo did not include DKK 6.3 billion in non-cash pipeline impairments. That item was 36% greater than the DKK 4.649 billion consensus beat. This comparison could clarify why headline gains did not resolve the quality discussion.
Management raised the outlook for the year. The midpoint of adjusted sales and profit each climbed by five percentage points.
| 2026 adjusted CER growth | May guidance | New guidance | Midpoint shift |
|---|---|---|---|
| Sales | -12% to -4% | -6% to 0% | up 5 points |
| Operating profit | -12% to -4% | -6% to 0% | up 5 points |
The pill showed the most robust commercial indicator. During the week ending July 17, weekly prescriptions for the Wegovy pill topped 265,000. Since launching in January, cumulative prescriptions surpassed five million.
The reported weekly prescription minimum increased by 32.5% compared with April. This figure represents a threshold comparison rather than a precise rate of growth.
CEO Mike Doustdar described the Wegovy portfolio as “a key growth driver.” He attributed the guidance hike to strong U.S. GLP-1 demand along with overseas rollouts. Novo Nordisk
The pill has yet to close the wider competitive divide. Prescriptions for Lilly’s Zepbound recently outnumbered Wegovy injections by over two to one. Still, oral Wegovy stayed in front of Lilly’s Foundayo, according to figures reported by Reuters.
Barclays Plc LON:BARC analyst James Gordon stated that Lilly’s pill “doesn’t really seem to have impacted the product.” Barclays issued a warning that the data excludes certain Foundayo distribution channels. Reuters
Management will update investors on Wednesday at 13:00 CEST. Discussion is expected to focus on pricing, refill rates and the 2027 growth bridge.
Risks: U.S. pricing headwinds, Lilly’s injectable frontrunner, and more setbacks in the pipeline could offset gains from oral Wegovy. Novo’s prospects for near-term diversification are limited after the ZEUS heart-disease trial failed.
The next decision will come from Copenhagen. The 8.6-point ADR gap offers the most straightforward near-term indication of whether this result has influenced conviction.
Related articles: NYSE:NVO
